Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
0%
0%
0.0%
6 Months
20.83%
0%
20.83%
1 Year
0%
0%
0.0%
2 Years
-25.64%
0%
-25.64%
3 Years
-71.43%
0%
-71.43%
4 Years
-93.01%
0%
-93.01%
5 Years
-92.56%
0%
-92.56%
N4 Pharma Plc for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
0.20%
EBIT Growth (5y)
-3.43%
EBIT to Interest (avg)
-1.23
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.63
Sales to Capital Employed (avg)
0.00
Tax Ratio
8.28%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.97
EV to EBIT
-3.08
EV to EBITDA
-3.08
EV to Capital Employed
3.52
EV to Sales
3.52
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-114.01%
ROE (Latest)
-60.49%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
Bullish
Bullish
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Dec'23
Dec'23
Dec'22
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-1.40
-1.20
-16.67%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-1.30
-1.00
-30.00%
Operating Profit Margin (Excl OI)
-729,438.80%
0.00%
-72,943.88%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2023 is 0.00% vs 0.00% in Dec 2022
Consolidated Net Profit
YoY Growth in year ended Dec 2023 is -30.00% vs 33.33% in Dec 2022
About N4 Pharma Plc 
N4 Pharma Plc
Pharmaceuticals & Biotechnology
N4 Pharma Plc, formerly Onzima Ventures plc, is a United Kingdom-based specialist pharmaceutical company. The Company is engaged in reformulating existing drugs and vaccines to improve their performance. It operates in two divisions: generic and vaccines. Its generics division includes Sildenafil, Sartans, Aprepitant and Single dose Hepatitis B. Its vaccines include Nuvac and Nuvec. The Company is improving Sildenafil for erectile dysfunction. Sartans is a family of drugs known as Angiotensin II antagonists, including Losartan and Valsartan, commonly used for the treatment of hypertension. Aprepitant is an anti-emetic drug used in oncology. It is reformulating the existing Hepatitis B surface antigen vaccine (HBsAg), a sub unit vaccine. Nuvac is a nano-carrier delivery system for vaccines. Nuvec is an engineered silica nanoparticle, which has been designed for the intracellular delivery of large nucleic acids such as plasmid deoxyribonucleic acid and messenger ribonucleic acid.
Company Coordinates 
Company Details
Weston House, 1 Bradgate Park View , DERBY None : DE73 5UJ
Registrar Details






